Pertuzumab patent expiry?

Pertuzumab (Perjeta) doesn’t have a single “one date” patent expiry—its market protection depends on multiple patents (product, process, formulations, combination use, jurisdiction-specific filings), plus regulatory exclusivities that can extend the effective protection period.

What’s known at a high level

• In the US: pertuzumab was approved in 2012. The primary composition/product-related patents were expected to expire in the mid-to-late 2020s, with possible extension effects depending on patent term adjustments and litigation/settlement outcomes.
• In the EU: protection was similarly tied to mid-to-late 2020s, again depending on which specific patents and exclusivities apply in each country.

To give you an accurate expiry date

I need 3 details:

1. Which country/region? (US, EU/EMA, UK, Canada, etc.)
2. Do you mean “first generic/biosimilar entry allowed” or “last patent expiry”?
3. Do you want the answer for pertuzumab alone or pertuzumab in combination (e.g., with trastuzumab ± chemo), which can matter for method-of-use patents?

If you tell me the region (e.g., US or EU) and which metric you want (last patent vs. market entry), I can narrow it down to the most relevant dates and the key patents/exclusivities that drive them.